This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Willett, C. G. Articles by Bendell, J. C. Search for Related Content PubMed PubMed Citation Articles by Willett, C. G. Articles by Bendell, J. C.

Radiation Therapy in Stage II and III Rectal Cancer

Authors' Affiliations: ¹ Department of Radiation Oncology and ² Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina

Requests for reprints: Christopher G. Willett, Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710. Phone: 919-668-5640; Fax: 919-668-7345; E-mail: christopher.willett{at}duke.edu.

Over the past 25 years, significant advances have been made in the management of patients with rectal cancer. Phase III studies have shown the efficacy of postoperative radiation therapy and chemotherapy in improving local control and survival of patients with resected stage II and III disease. Data from the randomized German CAO/ARO/AIO-94 trial of preoperative versus postoperative chemoradiation have provided a strong rationale and support for the use of preoperative chemoradiation in the treatment of patients with clinical stage II and III rectal cancer. Current phase III studies are evaluating novel combinations of chemotherapy and targeted agents with radiation therapy.